BIO Bio-Rad Laboratories Inc

Price (delayed)

$601.68

Market cap

$17.91B

P/E Ratio

4.37

Dividend/share

N/A

EPS

$137.71

Enterprise value

$17.45B

Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, ...

Highlights
The EPS has soared by 160% YoY and by 8% from the previous quarter
The net income has soared by 159% YoY and by 8% QoQ

Key stats

What are the main financial stats of BIO
Market
Shares outstanding
29.76M
Market cap
$17.91B
Enterprise value
$17.45B
Valuations
Price to earnings (P/E)
4.37
Price to book (P/B)
1.69
Price to sales (P/S)
6.64
EV/EBIT
3.28
EV/EBITDA
3.28
EV/Sales
6.46
Earnings
Revenue
$2.7B
EBIT
$5.32B
EBITDA
$5.32B
Free cash flow
$529.3M
Per share
EPS
$137.71
Free cash flow per share
$17.75
Book value per share
$355.48
Revenue per share
$90.56
TBVPS
$450.98
Balance sheet
Total assets
$13.93B
Total liabilities
$3.32B
Debt
$220.2M
Equity
$10.61B
Working capital
$1.57B
Liquidity
Debt to equity
0.02
Current ratio
3.57
Quick ratio
2.35
Net debt/EBITDA
-0.09
Margins
EBITDA margin
197.1%
Gross margin
56.3%
Net margin
151.7%
Operating margin
16.2%
Efficiency
Return on assets
33.4%
Return on equity
44.7%
Return on invested capital
49.7%
Return on capital employed
40%
Return on sales
197.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIO stock price

How has the Bio-Rad Laboratories stock price performed over time
Intraday
-0.21%
1 week
3.51%
1 month
0.89%
1 year
37.17%
YTD
3.21%
QTD
5.34%

Financial performance

How have Bio-Rad Laboratories's revenue and profit performed over time
Revenue
$2.7B
Gross profit
$1.52B
Operating income
$437.45M
Net income
$4.1B
Gross margin
56.3%
Net margin
151.7%
The net income has soared by 159% YoY and by 8% QoQ
The net margin has surged by 124% year-on-year
BIO's operating income has surged by 77% year-on-year and by 6% since the previous quarter
BIO's operating margin has surged by 53% year-on-year

Growth

What is Bio-Rad Laboratories's growth rate over time

Valuation

What is Bio-Rad Laboratories stock price valuation
P/E
4.37
P/B
1.69
P/S
6.64
EV/EBIT
3.28
EV/EBITDA
3.28
EV/Sales
6.46
The EPS has soared by 160% YoY and by 8% from the previous quarter
The price to earnings (P/E) is 95% lower than the 5-year quarterly average of 81.8 and 13% lower than the last 4 quarters average of 5.0
The equity has soared by 69% YoY and by 7% from the previous quarter
BIO's P/B is 11% below its 5-year quarterly average of 1.9
The stock's price to sales (P/S) is 66% more than its 5-year quarterly average of 4.0 and 3.8% more than its last 4 quarters average of 6.4
The revenue has grown by 16% YoY and by 6% from the previous quarter

Efficiency

How efficient is Bio-Rad Laboratories business performance
The ROS has soared by 123% YoY
Bio-Rad Laboratories's ROA has soared by 67% YoY but it has decreased by 4% from the previous quarter
The company's return on invested capital has surged by 66% YoY but it fell by 4.4% QoQ
The ROE has soared by 60% year-on-year but it is down by 5% since the previous quarter

Dividends

What is BIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIO.

Financial health

How did Bio-Rad Laboratories financials performed over time
The total assets has soared by 60% year-on-year and by 7% since the previous quarter
The company's current ratio rose by 49% YoY and by 5% QoQ
The debt is 98% smaller than the equity
Bio-Rad Laboratories's debt to equity has plunged by 80% YoY
The equity has soared by 69% YoY and by 7% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.